1-3 of 3
Patrick Simon Zbyszewski, MBA
Close
Sort by
Journal Articles

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Katherine P. Hearn, BSN, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney D DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Pierre Fenaux, MD PhD, Michael E. Petrone, MD MPH, Patrick Simon Zbyszewski, MBA, Steven M. Fruchtman, MD, Lewis R. Silverman, MD
Journal: Blood
Blood (2016) 128 (22): 3167.
https://doi.org/10.1182/blood.V128.22.3167.3167
Published: 2016
Journal Articles

Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

Guillermo Garcia-Manero, MD, Pierre Fenaux, MD PhD, Aref Al-Kali, MD, Shyamala C. Navada, MD, Maria R. Baer, MD, Azra Raza, MD, Peter Greenberg, MD, Karl-Anton Kreuzer, MD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Gail J. Roboz, Valeria Santini, MD, Uwe Platzbecker, MD, Michael E. Petrone, MD MPH, Bernard Brownstein, MD, Patrick Simon Zbyszewski, MBA, Manoj Maniar, PhD, Lewis R. Silverman, MD
Journal: Blood
Blood (2016) 128 (22): 2011.
https://doi.org/10.1182/blood.V128.22.2011.2011
Published: 2016
Journal Articles

A Genomic Predictive Signature for Rigosertib in Lower Risk MDS Derived By Integrating Clinical Response, Mechanism of Action Data and Simulation

Steven M. Fruchtman, MD, Abdullah Mahmood Ali, PhD, Michael E. Petrone, MD MPH, Patrick Simon Zbyszewski, MBA, Benjamin Hoffman, PhD, Shireen Vali, PhD, Neeraj Kumar Singh, Shahabuddin Usmani, Himanshu Grover, Taher Abbasi, Azra Raza, MD
Journal: Blood
Blood (2016) 128 (22): 5535.
https://doi.org/10.1182/blood.V128.22.5535.5535
Published: 2016